Zosano Pharma Corp (NASDAQ:ZSAN) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $80.00 for the company and are anticipating that the company will post ($4.80) EPS for the current quarter, according to Zacks. Zacks has also given Zosano Pharma an industry rank of 195 out of 265 based on the ratings given to related companies.
Separately, ValuEngine downgraded shares of Zosano Pharma from a “sell” rating to a “strong sell” rating in a research report on Tuesday, February 27th.
Institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. grew its position in shares of Zosano Pharma by 8.3% in the 4th quarter. Victory Capital Management Inc. now owns 257,673 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 19,680 shares during the period. Highlander Capital Management LLC bought a new position in shares of Zosano Pharma in the 4th quarter valued at about $104,000. Vanguard Group Inc. grew its position in shares of Zosano Pharma by 20.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,217,323 shares of the biotechnology company’s stock valued at $1,716,000 after acquiring an additional 209,251 shares during the period. Finally, Northern Trust Corp grew its position in shares of Zosano Pharma by 591.4% in the 2nd quarter. Northern Trust Corp now owns 79,234 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 67,774 shares during the period.
Zosano Pharma (NASDAQ:ZSAN) traded down $1.24 during trading on Thursday, reaching $17.25. 7,208,173 shares of the company were exchanged, compared to its average volume of 1,840,000. The company has a market capitalization of $34.04, a P/E ratio of -0.73 and a beta of 1.84. Zosano Pharma has a 1-year low of $3.61 and a 1-year high of $49.60.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.